Abstract:Our present view that the mood disorders involve dysfunction of monoaminergic system is a result of important clinical and preclinical observations over the past 40 years. The therapeutic efficacy of drugs such as the tricyclic antidepressants (TCAs), monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs) and lately of SNRIs (serotonin and norepinephrine reuptake inhibitors) helped to shape our view that mood regulation involves the monoaminergic systems in some way. It is thus little surprising when the neuropeptide, galanin, is discovered to coexist with norepinephrine (NE) in locus coeruleus (LC) neurons and with serotonin (5-HT) in the dorsal raphe nucleus (DRN) neurons, a link between galanin mediated signaling and mood regulation is sought. Galanin receptors are expressed in brain structures that are involved in the regulation of mood such as frontal cortex, amygdala, hypothalamus, LC, DRN and hippocampus. It is almost an accident of research fate that the potent effects of galanin on cognitive performance and seizure threshold have led galanin research to focus on the hippocampus where the neuropeptide is present in cholinergic and noradrenergic afferents and where the receptor density is much lower than in the monoaminergic nuclei. Hopefully it is not too late to report on the recent inroads into the roles of galanin and of galanin receptor subtypes 2 and 3 (GalR2 and GalR3) in mood regulation in animal models as well as in human patients with major depression. A body of existing data suggests that GalR2 signaling leads to antidepressant-like, anticonvulsant and neurogenesis-promoting effects, a spectrum of activities that are commonly associated with efficacious antidepressants. Similarly, GalR3 antagonists exhibit anxiolytic and antidepressant-like activity, another clinically useful combination for the treatment of mood disorders. Since both GalR2 and GalR3 are G-protein coupled receptors (GPCRs), a favorite target class for drug development, we believe that the pace of developing galaninergic antidepressants will increase significantly from now on.

Exploring the molecular structures that confer ligand selectivity for galanin type II and III receptors

Ligand binding properties of human galanin receptors

Molecular basis for allosteric agonism and G protein subtype selectivity of galanin receptors

Development of Spexin-based Human Galanin Receptor Type II-Specific Agonists with Increased Stability in Serum and Anxiolytic Effect in Mice

Theoretical investigation of selective ligand binding mode of galanin receptors

Single Hormone or Synthetic Agonist Induces Gs/Gi Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths.

Development of a high-throughput screening-compatible cell-based functional assay to identify small molecule probes of the galanin 3 receptor (GalR3)

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Pharmacological and functional characterization of galanin-like peptide fragments as potent galanin receptor agonists

Galanin, galanin receptors and drug targets

Galanin receptors as a potential target for neurological disease

Molecular Recognition of Metabotropic Glutamate Receptor Type 1 (mglur1): Synergistic Understanding with Free Energy Perturbation and Linear Response Modeling

Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease

Selective Polypeptide Ligand Binding to the Extracellular Surface of the Transmembrane Domains of the Class B GPCRs GLP-1R and GCGR

Structural Analysis of the Dual Agonism at GLP-1R and GCGR

The brain galanin receptors: targets for novel antidepressant drugs

Identifying Key Residues and Key Interactions for the Binding of LEAP2 to Receptor GHSR1a.

Molecular Determinant Underlying Selective Coupling of Primary G-Protein by Class A GPCRs

Novel systemically active galanin receptor 2 ligands in depression-like behavior

Molecular basis for the selective G protein signaling of somatostatin receptors

A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests